Welcome to our dedicated page for KIORA PHARMACEUTICALS news (Ticker: KPRX), a resource for investors and traders seeking the latest updates and insights on KIORA PHARMACEUTICALS stock.
Kiora Pharmaceuticals Inc (NASDAQ: KPRX) is a clinical-stage biotech company pioneering treatments for orphan retinal diseases through innovative platforms like molecular photoswitch technology and DHODH inhibitors. This page serves as the definitive source for official news and developments related to KIO-301 (vision restoration therapy) and KIO-104 (ocular inflammation treatment).
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones including orphan drug designations, and strategic partnerships advancing retinal disease therapies. Our curated collection features press releases on Phase 2 trial outcomes, manufacturing agreements, and peer-reviewed research collaborations.
Key content categories include updates on inherited retinal degeneration treatments, non-steroidal anti-inflammatory developments, and regulatory pathway advancements. All materials maintain strict compliance with financial disclosure standards while prioritizing accessibility for both professional and public audiences.
Bookmark this page for streamlined access to Kiora's latest scientific advancements and corporate announcements. Regularly updated content ensures you stay informed about critical developments in vision-restoring therapies and ocular inflammation management.
Kiora Pharmaceuticals (NASDAQ: KPRX) has appointed Lisa Walters-Hoffert as an independent member of its Board of Directors, effective July 1, 2024. Walters-Hoffert, a seasoned biotech executive, will serve as chair of the audit committee and join the compensation committee. Concurrently, Ken Gayron will step down from the board due to other commitments.
Lisa Walters-Hoffert brings extensive experience in strategic development, governance, finance, and capital markets to Kiora. Her appointment comes at a time when Kiora is advancing its pipeline of retinal disease treatments. Recently, Kiora has reported promising data on KIO-301 for retinal diseases, established a strategic co-development partnership, and secured financial resources to support its operations for at least the next two years, including investment in KIO-104 for inflammatory retinal diseases.
Kiora Pharmaceuticals (NASDAQ: KPRX) has announced the appointment of Dr. Roger A. Goldberg, a renowned vitreoretinal surgeon, to its Scientific Advisory Board on June 25, 2024. Dr. Goldberg, who is affiliated with Bay Area Retina Associates, brings extensive clinical and research expertise to Kiora. He has been involved in numerous clinical trials and has published extensively in top medical journals.
Dr. Goldberg will contribute to the development of Kiora's retinal disease therapeutics, including their investigational drug KIO-104, which targets overactive immune cells associated with conditions like macular edema and uveitis. His appointment is expected to enhance Kiora’s ability to advance treatment options for retinal diseases with high unmet needs. Dr. Goldberg’s background includes a medical degree from Yale, residency at Bascom Palmer Eye Institute, and a fellowship at Tufts University. He is board certified and actively engaged in several prestigious ophthalmology organizations.
Kiora Pharmaceuticals (NASDAQ: KPRX) will participate in two upcoming investor conferences. On May 22, at 3:00 pm ET, Executive VP of Finance Melissa Tosca will present at the WeBull Corporate Connect Biotech Investment Webinar. The event will be live and available on-demand for 90 days. On May 30, at 2:45 pm ET, President and CEO Brian Strem will join a virtual fireside chat at the Lytham Partners Spring 2024 Investor Conference. This event will also be live-streamed and available on-demand for 90 days. Kiora's management will hold one-on-one virtual meetings during the Lytham Partners event. Interested parties can arrange meetings by contacting Lytham Partners or registering for the event.
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) reported strong Q1 2024 financial results and updates on its retinal disease treatment pipeline. With $31.3 million in cash, Kiora is well-positioned to advance KIO-301 and KIO-104 into mid-stage clinical trials. The partnership with Théa Open Innovation (TOI) allows for efficient capital allocation. KIO-301 targets inherited retinal disorders, while KIO-104 addresses retinal inflammatory diseases. Positive milestones include successful Phase 1 trials and a strategic partnership with TOI. Financially, Kiora ended Q1 2024 with $31.3 million in cash, $16 million in revenue, and a net income of $13.5 million.
Kiora Pharmaceuticals (NASDAQ: KPRX) will be presenting at The Citizens JMP Life Sciences Conference on May 14th, 2024. Investors can access the online presentation live on the company's website and replay it for 90 days.
Kiora Pharmaceuticals released additional clinical data for KIO-301, a small molecule photoswitch, showing a significant increase in brain activity in the visual cortex of patients with retinitis pigmentosa. The data from the ABACUS-1 trial indicated improvements in visual field, visual acuity, and functional vision, along with an increase in neural activity that aligns with these improvements. The results were presented at the ARVO annual meeting by Professor Robert James Casson, supporting the drug's potential to restore vision.
FAQ
What is the current stock price of KIORA PHARMACEUTICALS (KPRX)?
What is the market cap of KIORA PHARMACEUTICALS (KPRX)?
